Insider buying last 90 days
No open-market insider purchases were filed for TLX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TLX insider filing, plotted on the chart in Gekko.Open TLX in Gekko
Telix Pharmaceuticals (TLX) Stock Analysis & Forecast
Oct 12 close
$11.29+0.08 (+0.7%)
Gekko Brief
AI summaryOct 12 closeTelix Pharmaceuticals moved this week on a string of product and partnership news. Profound Medical and Telix entered a co-education agreement to advance PSMA-informed prostate care, pairing Telix's PSMA-PET imaging with Profound's MRI-guided TULSA-PRO platform for physician education. Separately, Telix launched US commercial availability of its FDA-approved brain cancer imaging drug Pixclara, with the first US patients dosed; shares jumped 4.2% on the news, and one report framed the stock as potentially 35% below fair value on the Pixclara launch.
TLX closed at $11.29, up 0.7%, sitting between its 50-day average of $11.49 and 200-day average of $9.74. The GekkoIndex reads 59.2, placing the stock in the Neutral zone, down 2.5 over five days. Price sits 24.1% below Gekko Fair Value of $14.87. Over the past year the stock has returned 11.9%, with a 52-week range of $6.28 to $13.11.
No confirmed earnings date is on the calendar; the last report, on 19 August 2026, beat estimates ($0.11 actual versus $0.04 expected) with a 4.5% reaction, part of 3 beats in 8 quarters and an average absolute reaction of 11.6%. No insider, Congress, or unusual options activity appears in the current windows. Two covering analysts carry buy ratings, with a consensus target of $20.47. Typical 20-day price movement runs near 8.7%, worth noting given the recent string of product catalysts.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Telix Pharmaceuticals price vs fair value
Close $11.29200-day averageGekko Fair Value $14.87
Telix Pharmaceuticals quick facts
- Market cap
- $3.82B
- P/E ratio
- 110.1
- Forward P/E
- 140.9
- EPS, TTM
- $0.10
- Revenue, TTM
- $890.8M
- Profit margin
- 3.8%
- Dividend yield
- —
- Beta
- 0.56
- Volume
- 266,212 avg 491,656
- 1-year return
- +11.9%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±8.7%
- 50-day average
- $11.49
- 200-day average
- $9.74
- Next earnings
- —
- Shares outstanding
- 339.8M
Telix Pharmaceuticals swing-trade checklist
Telix Pharmaceuticals scores 1 supportive, 2 mixed and 0 headwinds across the 3 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $11.29 sits between the 50-day ($11.49) and 200-day ($9.74) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.2, Neutral
Reading 59.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
24.1% below
Price is 24.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Telix Pharmaceuticals stock chart and price history
Telix Pharmaceuticals closed at $11.29 on Oct 12, 2026, +11.9% over the past year, inside a 52-week range of $6.28 to $13.11.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- 0.0%
- 3 months
- +2.5%
- 6 months
- +0.4%
- 1 year
- +11.9%
The full TLX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TLX in Gekko
Follow Telix Pharmaceuticals through every session
Put TLX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TLX in GekkoFree for 7 days. No credit card required.
About Telix Pharmaceuticals
Telix Pharmaceuticals works on radiopharmaceuticals, medicines and imaging agents that use radioactive compounds to find and treat disease, with cancer care as a central focus. The company has already brought products to market and is best known for Illuccix and Gozellix, both used in prostate cancer care, alongside a pipeline of therapeutic and diagnostic candidates targeting cancers such as kidney cancer, glioblastoma, soft tissue sarcoma and bone metastases, as well as agents aimed at bone marrow conditioning ahead of stem cell transplants.
The business is structured around three areas: precision medicine, therapeutics, and manufacturing solutions. Its activities span early research candidates through to commercial products, and it has an academic collaboration with University Hospital Essen. Telix operates across several countries, including Australia, Belgium, Canada, the United Kingdom and the United States, pointing to a customer base and research presence that reaches beyond any single market.
Telix Pharmaceuticals was founded in 2015 and is headquartered in North Melbourne, Australia. Its shares trade under the ticker TLX.
- Sector
- Health technology
- Website
- telixpharma.com
Telix Pharmaceuticals GekkoIndex: the smart money zone
Telix Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.2, in the Neutral zone, down 2.5 points over five sessions.
59.2Neutral
Down 2.5 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 54 | +1.2% | −2.1% | ||
| Accumulation | 134 | −0.1% | +1.6% | ||
| Neutral (current zone) | 262 | 0.0% | −0.8% | ||
| Distribution | 21 | −2.7% | −3.3% | ||
| Selling | 0 | Not available | |||
Average TLX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TLX price, zone by zone.Track TLX in Gekko
Is Telix Pharmaceuticals stock overvalued? Gekko Fair Value
Telix Pharmaceuticals trades 24.1% below Gekko Fair Value of $14.87, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Telix Pharmaceuticals shares are worth, recalculated every trading day.
$14.87
Gekko Fair Value, Oct 10, 2026
24.1% Undervalued
At the end of Aug 2026 the price was 37.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TLX in Gekko
Telix Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Telix Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TLX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TLX, plotted on the chart in Gekko.Open TLX in Gekko
Telix Pharmaceuticals earnings: next date and track record
Telix Pharmaceuticals beat the EPS estimate in 3 of its last 8 reports, moving 11.6% on average across the report.
3 of 8reports beat the EPS estimate
±11.6%average move across the report
5 of 5reports followed by a gain
Share-price move across each report
Last earnings call, Aug 19, 2026 AI summary
- What they said
- Telix (TLX) reported H1 2026 precision medicine sales of approximately $390 million, up 27% year-on-year, driven by Gozellix launch and continued Illuccix growth. The company is tracking toward the upper end of guidance near $1 billion in revenue. Key milestones include PDUFA date of September 11 for Pixclara/Pixlumi, Zircaix resubmission in progress, and three Phase III therapeutic candidates advancing including TLX591 for prostate cancer.
- Guidance
- Management is tracking toward the upper end of full-year guidance, targeting close to $1 billion in revenue. Regulatory catalysts include a September 11 PDUFA date for Pixclara/Pixlumi and ongoing Zircaix resubmission with FDA on agreed timelines.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 19, 2026 | $0.11 est $0.04 | $477.0M est $479.6M | +4.5% |
| Feb 19, 2026 | $0.04 est $0.08 | $413.4M est $418.5M | +20.0% |
| Aug 20, 2025 | −$0.01 est $0.13 | $390.4M est $390.5M | +7.0% |
| Apr 22, 2025 | $0.09 est $0.00 | — | +12.9% |
| Feb 20, 2025 | $0.06 est $0.00 | $367.8M est $135.1M | +13.4% |
| Aug 22, 2024 | $0.06 est $0.09 | $246.5M est $237.8M | — |
| Feb 22, 2024 | $0.04 est $0.05 | $184.8M est $182.0M | — |
| Aug 23, 2023 | −$0.03 est $0.04 | $142.1M est $146.9M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Telix Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Telix Pharmaceuticals is $20.47, +81.3% from the last close, from 2 firms rating the stock in the last 90 days.
$20.47consensus 12-month target, +81.3% from the last close
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 30 | H.C. Wainwright | $20 | +77.1% |
| Sep 25 | H.C. Wainwright | $20 | +77.1% |
| Sep 22 | William Blair | — | — |
−0.8%average 20-day move after past Neutral readings
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Telix Pharmaceuticals market cap and key statistics
Telix Pharmaceuticals’s market cap is $3.82B, with a P/E ratio of 110.1 and revenue of $890.8M over the last twelve months.
Valuation
- Market cap
- $3.82B
- P/E ratio
- 110.1
- Forward P/E
- 140.9
- EPS, TTM
- $0.10
- Gekko Fair Value
- $14.87
Trading
- Volume
- 266,212
- Avg volume, 20 days
- 491,656
- 52-week high
- $13.11
- 52-week low
- $6.28
- Shares outstanding
- 339.8M
Financials
- Revenue, TTM
- $890.8M
- Profit margin
- 3.8%
- Return on equity
- 7.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.56
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±8.7%
Telix Pharmaceuticals stock news this week
Coverage of Telix Pharmaceuticals this week reads positive: 6 positive, 0 neutral and 0 negative headlines.
- Profound Medical signs Telix prostate imaging agreementgrafa.com, Oct 9
- Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CareGlobeNewsWire, Oct 9
- Telix Pharmaceuticals (ASX:TLX) Could Be 35% Below Fair Value On Pixclara LaunchSimply Wall Street, Oct 7
- Australian Shares Flat; Telix Pharmaceuticals Launches US Commercial Availability of Brain Cancer Imaging DrugMoomoo, Oct 7
- IU Health brain cancer patient one of first to receive new Telix Pharmaceuticals drugIndianapolis Business Journal, Oct 7
- Telix Pharmaceuticals shares jump on first US patient dosing for brain cancer imagingCapital Brief, Oct 7
Telix Pharmaceuticals stock FAQ
What is Telix Pharmaceuticals’s market cap?
Telix Pharmaceuticals’s market cap is $3.82B at the Oct 12, 2026 close of $11.29, with 339.8M shares outstanding. The shares trade on a P/E ratio of 110.1.
What is the Telix Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Telix Pharmaceuticals is $20.47, +81.3% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Telix Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Telix Pharmaceuticals is undervalued: the Oct 12, 2026 close of $11.29 is 24.1% below Gekko Fair Value of $14.87. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is Telix Pharmaceuticals’s 52-week high and low?
Telix Pharmaceuticals’s 52-week high is $13.11 and its 52-week low is $6.28; it closed at $11.29 on Oct 12, 2026, +11.9% over the past year. Over the last five years the shares peaked at $30.36 on Feb 24, 2025.
Is Telix Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 3 items with data read as supportive (fair value), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Telix Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.